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Purpose: Refractive error is caused by a disparity between the axial length and focusing power 
of the eye. Nanophthalmos is a rare ocular abnormality in which both eyes are abnormally small, 
typically causing extreme hyperopic refractive error, and associated with an increased risk of 
angle-closure glaucoma. 
Methods: A cohort of 40 individuals from 13 unrelated nanophthalmos kindreds were recruited, 
with 11 probands subjected to exome sequencing. 
Results: Nine probands (69.2%) were assigned a genetic diagnosis, with variants in PRSS56 (4), 
MFRP (3), and previously reported variants in TMEM98 (1) and MYRF (1). Two of the four 
PRSS56 probands harboured the previously described c.1066dupC frameshift variant implicated 
in over half of all reported PRSS56 kindreds, with surrounding haplotypes distinct from each other, 
and from a previously reported Tunisian c.1066dupC haplotype. Individuals with a genetic 
diagnosis had shorter mean axial lengths (P=7.22x10-9) and more extreme hyperopia (P=0.0005) 
than those without a genetic diagnosis, with recessive forms associated with the shortest axial 
lengths and highest hyperopia. All individuals with an axial length below 18 mm in their smaller 
eye (17/17) were assigned a genetic diagnosis. 
Conclusions: These findings detail the genetic architecture of nanophthalmos in an Australian 
cohort of predominantly European ancestry, their relative clinical phenotypes, and highlight the 





Clear vision requires precise regulation of ocular growth, such that the axial length of the eye 
matches the optical focal plane created by the cornea and lens. A discrepancy between the two 
results in refractive error, which is the leading cause of visual impairment and the second leading 
cause of blindness worldwide.1 Refractive error may be termed either myopia (where the focal 
point is in front of the retina) or hyperopia (where it falls behind it). Both forms of refractive error 
are correctable, although individuals at the extremes of refractive error are at an increased risk of 
irreversible blindness due to associated complications such as myopic macular degeneration, 
retinal detachment, or primary open-angle glaucoma (in the case of myopia); or strabismus, 
amblyopia, retinal detachment and angle-closure glaucoma (in the case of hyperopia).2 
 
Important insight into the developmental regulation of ocular axial length has come from the study 
of microphthalmia, which affects approximately 1 in 10,000 live births.3 Nanophthalmos and 
posterior microphthalmos are two rare subtypes of microphthalmia, both of which are associated 
with reduced axial length and high hyperopia.4 Posterior microphthalmos is characterised by 
reduced length of the posterior segment of the eye, with the anterior segment typically of normal 
length. Patients with posterior microphthalmos usually present with reduced visual acuity from an 
increase in the papillomacular retinal fold, occasional pigmentary retinopathy, and are susceptible 
to uveal effusions.5,6 Unlike posterior microphthalmos, nanophthalmos is characterized by a 
decrease in the size of both posterior and anterior segments, with a predisposition to primary 
angle-closure glaucoma.5,6 However, both posterior microphthalmos and nanophthalmos can be 
allelic7, supporting the hypothesis that they represent a continuum of the same phenotypic 
spectrum, rather than two distinct entities.8 
 
Posterior microphthalmos and nanophthalmos are commonly inherited as autosomal recessive 
traits, with variants in two genes accounting for the majority of known cases. The first of these, 
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MFRP (membrane frizzled-related protein), is expressed in retinal pigment epithelium and ciliary 
body, where a lack of MFRP disrupts emmetropization through an uncertain mechanism.9,10 Rare 
biallelic MFRP variants have been associated with nanophthalmos11, isolated posterior 
microphthalmos7, and posterior microphthalmos with retinitis pigmentosa, foveoschisis, and optic 
disc drusen12. Both MFRP-deficient mice13 and zebrafish14 have hyperopic phenotypes, 
consistent with a presumed loss-of-function mechanism in humans11. Viral transduction of wild-
type Mfrp into 5 day-old Mfrp mutant mice can also restore axial length13, suggesting that MFRP 
provides support for ocular development both in utero and after birth. 
 
A second gene, PRSS56 (protease, serine, 56), was initially identified in autosomal recessive 
nanophthalmos and posterior microphthalmos kindreds from the Faroe Islands, Tunisia, Canada, 
and Mexico.15–17 A chemically-induced mouse mutant at the orthologous locus showed close 
phenotypic parallels, with shortened axial length, hyperopia, and a propensity for angle closure.17 
Recent work has shown that PRSS56 is derived from late retinal progenitor cells or Müller glia, 
and promotes elongation of ocular axial length both before and after eye opening.18 PRSS56 
variants have also been implicated in multiple independent genome-wide association studies of 
myopia.19–21 
 
Autosomal dominant nanophthalmos is a less common clinical entity, and until recently only 
associated with variants in TMEM9822,23. Like PRSS56, TMEM98 has also been associated with 
myopia in a large genome-wide association study.21 A second dominant nanophthalmos locus, 
previously mapped to chromosome 1124, has now been associated with variants in MYRF, which 
encodes a transcriptional regulator that drives expression of TMEM98.25–28 
 
Here we assembled a cohort of 40 individuals across 13 nanophthalmos kindreds, describe their 







Individuals with nanophthalmos were recruited through the Australian and New Zealand Registry 
of Advanced Glaucoma29, and were included if they presented with bilateral and symmetrically 
small eyes, with an axial length less than 20 mm in both eyes. This threshold of 20 mm was 
previously shown to account for individuals below 3 standard deviations from the mean in the 
EPIC-Norfolk Eye Study, and proposed as a definition for nanophthalmos in the absence of any 
other standardised definition.30 Exclusion criteria included unilateral disease, anterior segment 
coloboma, and multiple non-ophthalmic syndromic features. Angle closure glaucoma status was 
assessed in all participants, yet was not a criterion for inclusion. Ocular hypertension was defined 
as an intraocular pressure (IOP) above 21 mmHg, with glaucoma defined as a glaucomatous 
visual field defect with a corresponding neuroretinal rim thinning. Previously reported families with 
variants in TMEM98 and MYRF were included in this cohort.23,28 Research followed the tenets of 
the Declaration of Helsinki with informed consent obtained from the subjects after explanation of 
the nature and possible consequences of the study. Ethics approval was granted by the Southern 
Adelaide Clinical Human Research Ethics Committee. 
 
Sequencing 
Exome sequencing and analysis was performed as previously described.31 Briefly, genomic DNA 
was extracted from venous blood samples using a QiaAmp DNA blood Maxi Kit (Qiagen), or from 
saliva using Oragene saliva DNA collection kits (DNA Genotek) according to the manufacturers' 
protocols. Exome capture was performed using the Agilent SureSelect system (v4 or v5) and 
paired-end libraries sequenced on an Illumina HiSeq (2000, 2500, or 4000). Read alignment and 
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variant calling were performed according to GATK best practices for germline short variant 
discovery (https://software.broadinstitute.org/gatk/). Variant annotation was performed using 
Variant Effect Predictor, with population frequencies from gnomAD and Bravo/TOPMed freeze 5 
collections.32 All putative causal variants were manually inspected in IGV. Capillary sequencing 
for MFRP or PRSS56 was performed using primer sequences available upon request. RNAseq 




Data were analysed with R (v3.6.1), with continuous variables displayed as mean ± SD (for 
normally distributed variables) or IQR (for non-normal variables), and categorical variables 
displayed as numbers and percentages. Mean values for axial length and spherical equivalent 
were calculated per individual using data from both eyes. P values were calculated by one-way 
ANOVA with Tukey multiple pairwise-comparison testing for normally distributed continuous 
variables, by Kruskal-Wallis test for non-normal continuous variables, or by Fisher’s exact test for 
categorical variables. One-way between-group analysis of covariance was used to compare 




We recruited a total of 40 individuals with nanophthalmos from 13 families. The mean age at 
recruitment was 47.5 ± 20.7 years, 57.5% were female, and 69.2% of families were of self-
reported European ancestry (European (9), mixed European/Indigenous Australian (1), Lebanese 
(1), Vietnamese (1), not reported (1)) (Figure 1A). Exome sequencing was performed on one or 
more affected individuals from each family, with the exception of family NNO03, in which a 
causative variant was identified by capillary sequencing. When including two previously reported 
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pedigrees23,28, a suspected genetic cause was identified in 9 of 13 kindreds (69.2%), in genes 
including PRSS56 (4), MFRP (3), TMEM98 (1), and MYRF (1) (Figure 1B, C, D, E). All variants 
were rare or absent in gnomAD, with CADD scores above 24, and recessive variants confirmed 
to be in trans by parental segregation testing (Table 1). Within tissues of dissected cadaveric 
human eyes33, expression of the dominant genes MYRF and TMEM98 was more similar to one 
another that to the recessive genes MFRP and PRSS56 (Figure 1F). 
 
 
Figure 1: Genetic characterisation of a nanophthalmos cohort. 
(A) Self-reported ancestry of the 13 probands. 
(B) Proportion of the cohort assigned likely pathogenic variants, and genes in which they occur. 
(C) PRSS56- and MFRP-associated pedigrees. Square symbols, male; round symbols, female; diagonal 
line, deceased; black filled symbols, affected (nanophthalmos); unfilled symbols, unaffected; black arrow, 
proband; double horizontal line, consanguinity. Genotypes of affected individuals displayed alongside each 
family identifier. 
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(D) Schematic of the PRSS56, MFRP, TMEM98, and MYRF loci, indicating the location of variants identified 
in the current study. Filled boxes indicate coding sequence, asterisks indicate genes with variants from 
previously reported pedigrees. 
(E) PRSS56, MFRP, TMEM98, and MYRF protein schematics, including domain structures and relative 
location of variants identified in the current study (white circles). Dashed vertical lines correspond to exon 
boundaries. C, cytoplasmic domain; TM, transmembrane domain; CUB, Complement C1r/C1s, Uegf, Bmp1 
domain; L, LDL-receptor class A domain; FZ, frizzled domain; CC, coiled-coil domain. 
(F) Relative mean expression (expressed a log counts per kb per million mapped reads) of four known 
nanophthalmos genes (TMEM98, MYRF, MFRP, PRSS56) in dissected human adult cadaveric eye tissue. 
S, sclera; CS, corneal stroma; CE, corneal epithelium; TM, trabecular meshwork; DM, Descemet’s 
membrane; ON, optic nerve; ONH, optic nerve head; PI, peripheral iris; CB, ciliary body. 
 
 
We identified four predicted pathogenic variants in MFRP across three probands, including one 
nonsense variant previously associated with nanophthalmos (p.(Gln175Ter))11, one splice site 
variant previously associated with retinitis pigmentosa (c.1124+1G>T)34, and two missense 
variants with no previous disease associations (p.(Ala570Val) and p.(Gly503Val)) (Figure 1D,E). 
 
Of the four probands with variants in PRSS56, all were found to have rare compound 
heterozygous or homozygous variants (Figure 1D,E, Table 1). These variants include previously 
unreported essential splice (c.849+1G>T and c.97+2dupT), frameshift (p.(Ala115GlyfsTer39)), 
and missense variants (p.(Arg564Cys)) predicted to be pathogenic, as well as two instances of 
the previously reported c.1066dupC frameshift variant. The PRSS56 c.1066dupC frameshift 
insertion (also reported as c.1059_1066insC, or p.(Gln356ProfsTer152)), had previously been 
reported in multiple Tunisian families with posterior microphthalmos (Figure 2A).15,17,35 A more 
recent study revealed that a c.1066dupC variant found in multiple Tunisian families was derived 
from a common ancestor around 1,850 years earlier.35 Another nine cases explained by the 
c.1066dupC variant have also been reported in a Saudi Arabian cohort of microphthalmia and 
posterior microphthalmos, accounting for 69% (9/13) of all cases with PRSS56 variants in this 
report8, as well as in Egyptian and Lebanese patients.36 It is not clear whether this was also due 
to a founder effect, although cohort ancestry (Saudi Arabian, Egyptian, and Lebanese) suggests 
that these cases were unlikely to share the Tunisian founder haplotype. 
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Table 1. Disease-associated gene variants in nine nanophthalmos probands. Genomic coordinates 
are based on the hg19 reference. AF, gnomAD r2.1.1 allele frequency; CADD, Phred-scaled CADD score. 
Variant consequences refer to the following transcript and protein accession IDs: TMEM98 
(ENST00000579849.1, ENSP00000463245.1), PRSS56 (ENST00000617714.1, ENSP00000479745.1), 
MFRP (ENST00000555262.1, ENSP00000450509.1), MYRF (ENST00000278836.5, 
ENSP00000278836.4). 
 
Family gene chr start ref alt state class cDNA protein AF CADD 
NNO03 MFRP 11 119214525 C A het splice donor c.1124+1G>T . 0.00006065 26.4 
NNO03 MFRP 11 119212289 G A het missense c.1709C>T p.Ala570Val 0.000004098 24.4 
NNO04 MFRP 11 119212574 C A het missense c.1508G>T p.Gly503Val . 25.6 
NNO04 MFRP 11 119216248 G A het stop gained c.523C>T p.Gln175Ter 0.00004022 36 
NNO08 MFRP 11 119214525 C A hom splice donor c.1124+1G>T . 0.00006065 26.4 




yfsTer36 . . 
NNO02 PRSS56 2 233387913 G T het splice donor c.849+1G>T . 0.00008335 24.5 




fsTer152 0.0003668 . 




fsTer152 0.0003668 . 
NNO22 PRSS56 2 233385406 - T hom splice donor c.97+2dupT . . . 




sTer39 0.000009972 . 
NNO27 PRSS56 2 233390091 C T het missense c.1690C>T p.Arg564Cys 0.00001887 33 
NNO01 TMEM98 17 31267907 G C het missense c.577G>C p.Ala193Pro . 29.5 
 
 
To determine the origin of the c.1066dupC frameshift variant in our two Australian kindreds, we 
compared surrounding haplotypes in NNO18, NNO02, and the previously described Tunisian 
founder haplotype (Figure 2B).35 Three phased variants were genotyped in both the NNO18 
proband and the Tunisian founder (rs733602, rs2245601, and rs2767), yet the genotypes in each 
were divergent, suggesting that the two alleles had arisen independently. Similarly, the NNO02 
haplotype included the C allele of rs2767 (compared to T in the Tunisian founder), suggesting 
that the c.1066dupC variant in NNO02 was also unlikely to have come from the Tunisian founder. 
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To compare the origins of the PRSS56 haplotypes in NNO02 and NNO18, we made use of a 
closely linked variant (rs79792358) in PRSS56 (149 bp downstream of c.1066dupC). This variant 
and the c.1066dupC insertion were both present in the NNO02 proband but absent from the 
NNO18 proband, suggesting that the NNO02 and NNO18 frameshift variants arose independently 
on different haplotypes (Figure 2B). 
 
 
Figure 2: The origins of PRSS56 c.1066dupC in a mutational hotspot. 
(A) Schematic of the PRSS56 protein, including domain structures and the relative location of variants 
identified in the current study (white circles), or in previous reports (coloured circles). Dashed vertical lines 
correspond to exon boundaries. 
(B) Comparative haplotype structure surrounding the PRSS56 c.1066dupC variant in the previously 
reported Tunisian founder, and two unrelated probands reported here (NNO18, NNO02). 
(C) Frequency of PRSS56 loss-of-function variants (nonsense, essential splice, frameshift) reported in the 
gnomAD r2.0.2 and Bravo (TOPMed Freeze5) collections. The c.1066dupC variant is highlighted in red. 
(D) Allele frequency of the c.1066dupC variant across multiple ancestries within gnomAD r2.0.2. 
(E) IGV representation of the left-shifted c.1066dupC variant in the context of the cytosine mononucleotide 
repeat. 
 
The c.1066dupC frameshift insertion was the most frequent loss-of-function PRSS56 variant in 
the gnomAD collection of genomes and exomes (Figure 2C), representing over half (58/112) of 
11 
all reported PRSS56 loss-of-function variants. These 58 c.1066dupC variants were distributed 
across seven ancestral populations at allele frequencies between 2.5 x 10-4 and 6.9 x 10-4, 
consistent with the independent emergence of c.1066dupC variants in multiple populations 
(Figure 2D). PRSS56 c.1066 was also noted to be a multiallelic site, with insertions and deletions 
reported at the same position (Figure 2C), both of which altered the length of an eight nucleotide 
cytosine mononucleotide repeat (Figure 2E). 
 
 
Figure 3: Genetic diagnosis is associated with shorter axial lengths and increased hyperopia. 
Ocular axial length (A) and spherical equivalent (B) of affected family members stratified by genetic 
diagnosis. Mean values were calculated per individual using data from both eyes. For both comparisons, 
group means were significantly different by one-way ANOVA (P<0.0003), with asterisks (*) indicating a 
significant difference from the unsolved cohort (Tukey multiple comparison testing, P<0.003). 
 
Individuals with suspected pathogenic variants in PRSS56, MFRP, TMEM98, or MYRF had 
reduced ocular axial length (Figure 3A, Table 2), with the majority also highly hyperopic (Figure 
3B, Table 2). The mean axial length was significantly shorter in groups with a genetic diagnosis 
compared to those without (P=7.22x10-9), with the PRSS56 subset also having a shorter mean 
axial length than the dominant TMEM98 (adjusted P=0.00003) and MYRF (adjusted P=0.00004) 
subsets (Figure 3A). All groups also had a significantly higher mean refractive error (P=0.0005), 
with PRSS56 and MFRP groups more hyperopic than nanophthalmic individuals without a genetic 
diagnosis (Figure 3B, Table 2). Across the entire cohort and in those where data were available, 
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22.6% (7/31) had glaucoma, and 43.3% (13/30) had a pressure-lowering surgical intervention in 
at least one eye (laser peripheral iridotomy, selective laser trabeculoplasty, or trabeculectomy). 
Neither of these variables showed a significant difference between the genetic diagnosis groups 
(P=0.6665 and P=1.0000 respectively), even after adjusting for age at recruitment (Table 2). 
 
Table 2. Summary of genotype-phenotype correlates. Continuous variables are displayed as mean ± 
SD (for normally distributed variables) or IQR (for non-normal variables), with categorical variables 
displayed as numbers and percentages. P values were calculated by one-way ANOVA for normally 
distributed variables, Kruskal-Wallis test for non-normal continuous variables, or by Fisher’s exact test for 
categorical variables. AL, axial length; AC, anterior chamber; SE, spherical equivalent; MD, mean deviation; 
SD, standard deviation; IQR, interquartile range.  
 
 Unsolved MYRF TMEM98 MFRP PRSS56 P 
n 6 5 16 4 9  
Gender = F/M (%) 5/1 (83.3/16.7) 2/3 (40.0/60.0) 7/9 (43.8/56.2) 4/0 (100.0/0.0) 
5/4 
(55.6/44.4) 0.1937 
Age at recruitment (mean 
(SD)) 56.83 (11.27) 28.40 (20.21) 51.38 (22.43) 55.50 (9.75) 34.67 (17.34) 0.033 
AL (mean (SD)) 19.27 (0.52) 18.01 (0.31) 17.66 (0.62) 16.44 (0.64) 15.76 (0.74) <0.0001 
SE (mean (SD)) 9.04 (0.83) 9.38 (3.64) 11.79 (2.43) 15.62 (2.33) 14.77 (3.66) 0.0005 












Glaucoma = No/Yes (%) 5/1 (83.3/16.7) 4/0 (100.0/0.0) 6/4 (60.0/40.0) 3/1 (75.0/25.0) 
6/1 
(85.7/14.3) 0.6665 
IOP intervention = 






Here we described an Australian nanophthalmos cohort of predominantly European ancestry in 
which 53.8% (7/13) of families were explained by variants in MFRP or PRSS56, or 69.2% (9/13) 
when including previously reported families with variants in TMEM98 or MYRF.23,28 Mean axial 
length was shorter in all four groups of individuals with a genetic diagnosis compared to those 
without, with the recessive PRSS56 and MFRP forms associated with the shortest axial length. 
Similarly, hyperopia was higher in affected individuals with a known genetic diagnosis compared 
to those without. This suggests that individuals with milder nanophthalmos phenotypes may be 
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explained by variants in other genes, and emphasises the importance of prioritising genetic testing 
for MFRP and PRSS56 in individuals with the most severe nanophthalmos phenotypes. 
 
All individuals with an axial length below 18 mm in their smaller eye had a genetic diagnosis 
(17/17), with all but one under 17 mm associated with variants in either PRSS56 or MFRP (10/11). 
Previous population studies have shown these thresholds to capture 0.137% (<18 mm) and 
0.05% (<17 mm) of an adult British population30, and we propose that these be considered a 
threshold for identifying an underlying single gene cause. 
 
PRSS56 was the most commonly implicated gene in this cohort (4/13, 30.8%) and in other cohorts 
of posterior microphthalmos and nanophthalmos (27.3% - 61.5%).8,26,36 Including the four 
described here, at least 32 pedigrees have been described with PRSS56-associated posterior 
microphthalmos or nanophthalmos.8,15–17,26,35,36 Twenty of these pedigrees (62.5%) share the 
same c.1066dupC frameshift insertion variant, or 55.6% (15/27) if one considers the six Tunisian 
pedigrees with a shared haplotype as a single extended pedigree.17,35 Two of the families reported 
here harbour the c.1066dupC variant on at least one allele, which lay on haplotypes distinct from 
each other and from the previously reported Tunisian pedigree, suggesting the existence of a 
mutational hotspot in PRSS56. These variants arose in the context of an eight nucleotide cytosine 
mononucleotide repeat, which is incidentally a frequent occurrence in MYRF-associated 
nanophthalmos and high hyperopia28, and is likely secondary to slipped-strand mispairing during 
DNA replication.37 
 
While loss-of-function variants such as PRSS56:c.1066dupC are associated with reduced axial 
length and hyperopia, variants that enhance the activity of PRSS56 might be expected to lead to 
increased axial length and myopia. The p.(Ala30Thr) variant of PRSS56 is one of the few protein-
coding variants to have emerged from genome-wide association studies of refractive error. Unlike 
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the loss-of-function variants described here which associate with hyperopia, p.(Ala30Thr) is 
associated with myopia, suggesting that it may increase axial length through a gain-of-function 
mechanism.20 PRSS56 itself is a soluble serine protease, potentially sensitive to protease 
inhibitors or monoclonal antibodies, and therefore would be a candidate therapeutic target in the 
treatment of refractive error. It has already been shown that deletion of Prss56 can reduce axial 
length and correct refractive error in an Egr1 mutant mouse model of myopia18, raising the 
possibility that PRSS56 inhibitors might be applied to the treatment of myopia in humans. 
 
In summary, we present the genetic landscape of nanophthalmos in an Australian cohort, 
revealing a considerable overlap between genes associated with rare and common refractive 
error phenotypes. The shortest axial length and most extreme hyperopic refractive error were 
associated with autosomal recessive forms of nanophthalmos (PRSS56 and MFRP), with a less 
extreme phenotype in autosomal dominant forms (TMEM98 and MYRF). Finally, we 
demonstrated that the most frequent single variant associated with nanophthalmos across all 
ancestries, PRSS56 c.1066dupC, is likely to have arisen independently in at least four different 
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